Concepedia

Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): Tolerance and relation to leukocyte and buccal cell platinum-DNA adducts

Inderbir S. Gill, Franco M. Muggia, P M Terheggen, Con Michael, R. J. Parker, Virginia L. Kortes, Steven M. Grunberg, Michaele C. Christian, E Reed, L. Den Engelse

Annals of Oncology · 1991 · 39 citations · 13 references

DOI

Concepts

References

13

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

, , +8

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

A. Hilary Calvert, David R. Newell, Lindsey Gumbrell et al. · Journal of Clinical Oncology · 1989 · 1.9K citations

, , +17

Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

Richard J. Knox, Frank Friedlos, David Lydall et al. · PubMed · 1986 · 499 citations

, , +15

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

Thomas C. Shea, M Flaherty, Alby Elias et al. · Journal of Clinical Oncology · 1989 · 193 citations

, , +17

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

Merrill J. Egorin, David A. Van Echo, Eve A. Olman et al. · PubMed · 1985 · 191 citations

, , +17